The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.

The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
In comments to the CMS, the ACR advocated for telehealth flexibilities and fair reimbursement and pushed back on proposed efficiency adjustments and changes likely to increase administrative burden on practices.
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
The new Rural Health Transformation Program offers states the chance to apply for CMS funding aimed at transforming rural healthcare.
The Practice Innovation Summit, to be held in Chicago Oct. 24–25, offers a roadmap to a smarter, stronger rheumatology practice, led by experts in operations, coding, financial sustainability and more.
A rheumatologist with a background in biostatistics, data science & bioinformatics discusses the use of artificial intelligence in clinical research.
What does it take to become a master in rheumatology? Explore how deliberate practice, relentless curiosity & profound humility are key to true expertise.
Fulfill your lifelong learning goals with the ACR & ARP. Explore diverse educational options, including journals, podcasts & ACR Convergence 2025.